New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

Now that investors have demonstrated demand for biotech IPOs that has led to a warm reception for new listings over the past few weeks, the queue has begun to grow again, as a handful of preclinical biotechs filed prospectuses late Friday for NASDAQ offerings.

The group includes gene therapy company Generation Bio Co., antibody-oligonucleotide conjugate developer Avidity Biosciences Inc. and vaccine company Vaxcyte Inc., which

Read the full 642 word article

How to gain access

Continue reading with a
two-week free trial.